HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
CN Stock MarketDetailed Quotes
002422 Sichuan Kelun Pharmaceutical
- 27.38
- +0.03+0.11%
Not Open Feb 18 15:00 CST
43.85BMarket Cap14.79P/E (TTM)
27.95High27.00Low213.92KlotVolume27.33Open27.35Pre Close587.88MTurnover1.64%Turnover Ratio17.85P/E (Static)1.60BShares34.9352wk High1.94P/B35.83BFloat Cap24.4652wk Low30.09Limit Up1.31BShs Float34.93Historical High24.62Limit Down3.47%Amplitude7.80Historical Low1.06Dividend TTM27.48Avg Price91.72KlotAsk3.87%Div YieldTTM100Lot Size113.17KlotBid
Sichuan Kelun Pharmaceutical News
Colon Pharmaceuticals: Announcement on the research results of the subsidiary\'s core product, lucansastuzumab (SAC-TMT), presented at the 2025 American Society of Clinical Oncology Urogenital Cancer Symposium
Colon Pharmaceutical: Announcement on the company\'s approval for drug registration for injectable imipenem and cistatin sodium/sodium chloride injections
Colon Pharmaceutical: Announcement on the approval for marketing of its subsidiary cetuximab N01 injection by the State Drug Administration
Colon Pharmaceutical: Announcement on the approval of the subsidiary SKB445 clinical trial application for the new drug by the State Drug Administration
Colon Pharmaceutical: Announcement on the approval of the subsidiary anti-PD-L1 tagolimab for marketing by the State Drug Administration
Colon Pharmaceuticals: Legal Opinion of the 2025 First Extraordinary General Meeting of Shareholders of Colon Pharmaceuticals
Colon Pharmaceuticals: Announcement of Resolutions of the 2025 First Extraordinary General Meeting of Shareholders
Colon Pharmaceuticals: Announcement on Cancelling Part of the Repurchased Shares, Reducing Registered Capital, and Notifying Creditors
Colon Pharmaceuticals: Announcement on the subsidiary\'s exclusive licensing agreement for SKB378/HBM9378
Colon Pharmaceutical: Announcement on the Company\'s Lutripopa Tablets Obtaining Drug Registration Approval
Colon Pharmaceutical: Announcement on the acceptance of the new drug application for the subsidiary\'s core product Bodutrazumab by the State Drug Administration
Colon Pharmaceuticals: Announcement on the Company\'s Cloverdipine Emulsive Injection Obtaining Drug Registration Approval
Colon Pharmaceutical: Announcement on the approval of the subsidiary anti-PD-L1 tagolimab for marketing by the State Drug Administration
Colon Pharmaceuticals: Announcement on the completion of the sale of shares in the 2022 Employee Stock Ownership Plan
Colon Pharmaceuticals: Announcement on the launch of foreign exchange hedging business by the company and its subsidiaries
Colon Pharmaceutical: Announcement on the expected daily related transactions between the company and Shijiyao Group in 2025
Colon Pharmaceuticals: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2025
Colon Pharmaceutical: “Constitution of Sichuan Colon Pharmaceutical Co., Ltd.” (December 2024)
Colon Pharmaceuticals: Announcement on Adjusting the Use and Cancellation of Some Repurchased Shares
Colon Pharmaceutical: Announcement on the expected daily related transactions between the company and Chenxin Pharmaceutical Group in 2025